FDA Clears Baxter’s Bone Graft Substitute

Baxter International announced that it has received FDA clearance for its Actifuse Flow bone graft substitute.

Delivered in a prepackaged syringe, the product can be used in a variety of orthopedic surgeries and no mixing or preparation is necessary. Baxter expects Actifuse Flow to be used in a variety of orthopedic surgeries in the pelvis, extremities, and posterolateral spine.

The bone graft substitute increases silicon levels, thereby accelerating bone formation. It is replaced by the patient’s own bone during the body’s healing process.